Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Masking of erbB2 may underlie Herceptin resistance
March 24th, 2005
Masking of erbB2 may underlie Herceptin resistance in breast tumors. "Overexpression of erbB2 in breast tumors is associated with poor prognosis and is a target of receptor-oriented cancer therapy," oncologists in Germany explained. "Trastuzumab (Herceptin), a monoclonal antibody against a membrane-proximal epitope in the extracellular region of erbB2, shows a therapeutic effect against a fraction of erbB2-amplified breast tumors." "Unfortunately, resistance to Herceptin is common, and its cause is as yet unclear," noted P. Nagy and colleagues at the Max Planck Institute for Biophysical Chemistry. In a recent study, they "investigated the...
Source: Women's Health Weekly (2005-03-24)
|
